Found: 15
Select item for more details and to access through your institution.
Inflammatory Biomarkers as Predictors of Response to Immunotherapy in Urological Tumors.
- Published in:
- Journal of Oncology, 2019, p. 1, doi. 10.1155/2019/7317964
- By:
- Publication type:
- Article
Immune System and DNA Repair Defects in Ovarian Cancer: Implications for Locoregional Approaches.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 10, p. 2569, doi. 10.3390/ijms20102569
- By:
- Publication type:
- Article
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.
- Published in:
- Frontiers in Oncology, 2023, p. 1, doi. 10.3389/fonc.2023.1221096
- By:
- Publication type:
- Article
Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients.
- Published in:
- Frontiers in Oncology, 2023, p. 01, doi. 10.3389/fonc.2023.1221096
- By:
- Publication type:
- Article
Erratum to: Multicenter Institutional Experience of Surgically Resected Thymic Epithelial Tumors (TETs): An Observational Report on Behalf of F.O.N.I.C.A.P. (Forza Operativa Nazionale Interdisciplinare Contro il Cancro del Polmone)
- Published in:
- 2013
- By:
- Publication type:
- Correction Notice
Plasma Androgen Receptor in Prostate Cancer.
- Published in:
- Cancers, 2019, v. 11, n. 11, p. 1719, doi. 10.3390/cancers11111719
- By:
- Publication type:
- Article
Melphalan as a Promising Treatment for BRCA-Related Ovarian Carcinoma.
- Published in:
- Frontiers in Oncology, 2021, v. 11, p. 1, doi. 10.3389/fonc.2021.716467
- By:
- Publication type:
- Article
Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Testosterone levels and androgen receptor copy number variations in castration‐resistant prostate cancer treated with abiraterone or enzalutamide.
- Published in:
- Prostate, 2019, v. 79, n. 11, p. 1211, doi. 10.1002/pros.23804
- By:
- Publication type:
- Article
Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.
- Published in:
- Prostate, 2014, v. 74, n. 16, p. 1691, doi. 10.1002/pros.22890
- By:
- Publication type:
- Article
Caregiver Emotional Burden in Testicular Cancer Patients: From Patient to Caregiver Support.
- Published in:
- Frontiers in Endocrinology, 2019, p. N.PAG, doi. 10.3389/fendo.2019.00318
- By:
- Publication type:
- Article
CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.
- Published in:
- International Journal of Biological Markers, 2016, v. 31, n. 3, p. e264, doi. 10.5301/jbm.5000197
- By:
- Publication type:
- Article
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
- Published in:
- Oncologist, 2017, v. 22, n. 7, p. 784, doi. 10.1634/theoncologist.2017-0154
- By:
- Publication type:
- Article
Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.
- Published in:
- Scientific Reports, 2018, v. 8, n. 1, p. 1, doi. 10.1038/s41598-018-33774-4
- By:
- Publication type:
- Article
Potential Application of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Renal Cell Tumors.
- Published in:
- Frontiers in Oncology, 2020, v. 10, p. N.PAG, doi. 10.3389/fonc.2020.565857
- By:
- Publication type:
- Article